| Name | 5-BrdU |
| Description | 5-BrdU (Broxuridine) is a nucleoside analogue. 5-BrdU is used to detect proliferating cells and compete with thymidine for incorporation into DNA. |
| Cell Research | Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 μM BrdU for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.(Only for Reference) |
| Kinase Assay | Assays are run in the presence of 100 μM ATP using 10 μM of substrate. 30 μL PROTEIN-MIX in 25% DMSO and incubated for 15 min at room temperature. 10 μL PEPTIDE-MIX is added, the mixture is incubated for 60 min at RT and stopped by adding 180 μL 6.4% TCA (final concentration: 5%). Incorporated phosphate is measured in a scintillation counter and IC50 values are calculated using a sigmoidal curve analysis program with variable hill slope[1]. |
| In vitro | METHODS: Mouse neural precursor cells were treated with 5-BrdU, and the cell proliferation activity was detected by MTT.
RESULTS: The EC50 value of the anti-proliferation activity of 5-BrdU was 2.045μM. [1]
METHODS: L5178Y mouse leukemia cells were treated with 5-BrdU, and the growth inhibition of the cells was determined by growth inhibition.
RESULTS: In L5178Y mouse leukemia cells, the IC50 values of 5-BrdU were 20μM (determined by [14C] leucine incorporation) and 26μM (determined by [14C] thymidine incorporation), respectively. [2] |
| In vivo | METHODS: To study the anti-tumor activity of 5-BrdU, 5-BrdU was intraperitoneally injected (300 mg/kg) or orally administered (0.8 mg/mL) in the rat glioma RG2 tumor model.
RESULTS: 5-BrdU significantly slowed down the progression of the tumor. [3]
METHODS: To study the effect of exposure during the embryonic period on the cerebellar neuroepithelium of mice, pregnant rats were injected with different doses (25-300 µg/g) of 5-BrdU at a single time on the 13th day of the embryo.
RESULTS: Low doses (25-75 µg/g) of 5-BrdU did not change the proliferation behavior of cerebellar neuroepithelial cells, while high doses (100-300 µg/g) led to a decrease in related proliferation parameters, among which the effect of the 300 µg/g dose was the most significant. [4]
METHODS: To study the effect of 5-BrdU on neuroblasts in the granular layer outside the cerebellum of mice, different doses (50-300 µg/g) of 5-BrdU were injected once on the 9th day after the birth of mice.
RESULTS: Different doses of 5-BrdU can affect the duration of each stage of the cell cycle and the completion time of the entire cell cycle. [4]
METHODS: To investigate the effect of 5-BrdU on neurogenesis in the hippocampal dentate gyrus of adult rats, adult rats were treated with cumulative doses of 5-BrdU (40, 240 or 460 mg/kg).
RESULTS: 5-BrdU did not reduce cell proliferation or the number of immature neurons in the dentate gyrus of the hippocampus. [5] |
| Storage | keep away from direct sunlight,store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 2 mg/mL (6.51 mM), Sonication is recommended.
H2O : 15.4 mg/mL (50.15 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (16.28 mM), Sonication is recommended.
DMSO : 242.5 mg/mL (789.65 mM), Sonication is recommended.
|
| Keywords | NucleosideAntimetabolite | Nucleoside Antimetabolite/Analog | Nucleoside Antimetabolite | Inhibitor | inhibit | Analog | 5-BrdU | 5BrdU | 5 BrdU |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Adenine hemisulfate | Erythromycin thiocyanate | Uridine | Guanidine hydrochloride | Hexane-1,6-diol | 1,4-Naphthoquinone | Adenine | Carbazole | Thymidine | Usnic Acid |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Covalent Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library | Nucleotide Compound Library |
United States
